Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Ropert

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 18, 2017
Colchicine is an active treatment for everolimus-induced oral ulcersStanislas Ropert, Romain Coriat, Benjamin Verret, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 31, 2012
Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control studyOlivier Mir, Jean-Philippe Durand, Pascaline Boudou-Rouquette, et al.
Molecular Cancer Therapeutics|August 21, 2012
Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivoRomain Coriat, Carole Nicco, Christiane Chéreau, et al.
Anti-Cancer Drugs|September 16, 2005
Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbiditiesOlivier Mir, Jérôme Alexandre, Stanislas Ropert, et al.
The Oncologist|July 4, 2012
Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysisPascaline Boudou-Rouquette, Stanislas Ropert, Olivier Mir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenibNathalie Franck, Stéphane Barete, Philippe Moguelet, et al.
Journal of Oncology Practice|November 28, 2012
Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapyRomain Coriat, Pascaline Boudou-Rouquette, Jean-Philippe Durand, et al.
Investigational New Drugs|May 27, 2011
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patientsOlivier Mir, Jérôme Alexandre, Romain Coriat, et al.
The Oncologist|August 3, 2011
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activityOlivier Mir, Romain Coriat, Laure Cabanes, et al.
Investigational New Drugs|November 1, 2011
Sorafenib exposure decreases over time in patients with hepatocellular carcinomaJennifer Arrondeau, Olivier Mir, Pascaline Boudou-Rouquette, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|October 18, 2017
Colchicine is an active treatment for everolimus-induced oral ulcersStanislas Ropert, Romain Coriat, Benjamin Verret, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 31, 2012
Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control studyOlivier Mir, Jean-Philippe Durand, Pascaline Boudou-Rouquette, et al.
Molecular Cancer Therapeutics|August 21, 2012
Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivoRomain Coriat, Carole Nicco, Christiane Chéreau, et al.
Anti-Cancer Drugs|September 16, 2005
Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbiditiesOlivier Mir, Jérôme Alexandre, Stanislas Ropert, et al.
The Oncologist|July 4, 2012
Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysisPascaline Boudou-Rouquette, Stanislas Ropert, Olivier Mir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenibNathalie Franck, Stéphane Barete, Philippe Moguelet, et al.
Journal of Oncology Practice|November 28, 2012
Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapyRomain Coriat, Pascaline Boudou-Rouquette, Jean-Philippe Durand, et al.
Investigational New Drugs|May 27, 2011
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patientsOlivier Mir, Jérôme Alexandre, Romain Coriat, et al.
The Oncologist|August 3, 2011
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activityOlivier Mir, Romain Coriat, Laure Cabanes, et al.
Investigational New Drugs|November 1, 2011
Sorafenib exposure decreases over time in patients with hepatocellular carcinomaJennifer Arrondeau, Olivier Mir, Pascaline Boudou-Rouquette, et al.
Pageof 6